Lev Radin / Shutterstock.com
24 August 2021Big PharmaAlex Baldwin
Regeneron asks court to dismiss COVID-19 tech patent suit
Regeneron wants a Manhattan district court to toss a lawsuit that claims it infringed on patents in the development and testing of COVID-19 treatments.
Already registered?
Login to your account
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
Big Pharma
8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
29 August 2019 A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
11 November 2021 The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.
Editor's picks
Editor's picks
Big Pharma
8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
29 August 2019 A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
11 November 2021 The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.
Big Pharma
8 March 2021 On June 24, 2020, a seven-year long legal battle between two biotech companies finally concluded in the UK.
Americas
29 August 2019 A US judge yesterday, August 28 ruled in favour of Sanofi and Regeneron in the pharmaceutical companies’ long-running patent dispute with Amgen over the cholesterol drug Praluent.
Big Pharma
11 November 2021 The US Patent Trial and Appeal Board will review the validity of two Regeneron Pharmaceuticals patents related to its Eylea (aflibercept) medication.